10:01 AM EDT, 05/30/2025 (MT Newswires) -- GE Healthcare Technologies ( GEHC ) said Friday the NCCN clinical practice guidelines in oncology for doctors now recommend considering the use of fluoroestradiol, or FES, positron emission tomography, or PET, imaging in some individuals with lobular breast cancer.

The company said its cerianna injection is the only imaging agent approved by the US Food and Drug Administration to detect estrogen receptor positive breast cancer metastases, including lobular breast cancer.

GE Healthcare ( GEHC ) said invasive lobular cancer is the second most common type of breast cancer in the US.

Price: 70.05, Change: -1.48, Percent Change: -2.07